Evidence map›Paper›PMID 39135190›Full record

ReviewAdvances in rheumatology (London, England)2024

Sarcoidosis: a general overview.

Fabricio Souza Neves, Ivanio Alves Pereira, Flavio Sztajnbok, Nilton Salles Rosa Neto

Abstract readReview
In one paragraph

Review in Advances in rheumatology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Unveiling novel susceptibility genes for sarcoidosis by a cross-tissue transcriptome-wide association study.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fabricio Souza NevesInternal Medicine Department, Rheumatology Division, Health Sciences Center, Universidade Federal de Santa Catarina (UFSC), Florianópolis, Brazil. fabricio.souza.neves@ufsc.br.ORCID 0000-0002-8725-4526
Ivanio Alves PereiraMedicine School, Rheumatology Division, Universidade do Sul de Santa Catarina (UNISUL), Palhoça, Brazil.
Flavio SztajnbokDepartment of Pediatrics, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Nilton Salles Rosa NetoCentro de Doenças Raras e da Imunidade, Hospital Nove de Julho, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoidosis is a systemic inflammatory disease of unknown origin, which consists of the formation of multiple sterile noncaseating granulomas. Inhaled antigens are believed to initiate disease in prone individuals, considering that almost all patients present pulmonary or mediastinal lymph node disease. Extrapulmonary manifestations are common and diverse: practically any organ system can be affected, and treatment can range from simple watchful waiting to intense immunosuppression. In this article, we review current concepts about sarcoidosis in an overview, focusing on recognition and treatment of its major clinical phenotypes.

Indexed as

SarcoidosisHumansSarcoidosis, PulmonaryNoncaseating granulomaRare diseasesReviewSarcoidosis

Identifiers

PMID39135190
PMCPMC13488721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.